Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Two susceptibility loci identified for prostate cancer
aggressiveness
Gerald Andriole
Washington University School of Medicine in St. Louis

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Andriole, Gerald and et al., ,"Two susceptibility loci identified for prostate cancer aggressiveness." Nature
Communications. 6,. 6689. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4111

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

ARTICLE
Received 24 Jun 2014 | Accepted 10 Mar 2015 | Published 5 May 2015

DOI: 10.1038/ncomms7889

Two susceptibility loci identiﬁed for prostate cancer
aggressiveness
Sonja I. Berndt1,*, Zhaoming Wang1,2,*, Meredith Yeager1,2, Michael C. Alavanja1, Demetrius Albanes1,
Laufey Amundadottir1, Gerald Andriole3, Laura Beane Freeman1, Daniele Campa4, Geraldine Cancel-Tassin5,
Federico Canzian6, Jean-Nicolas Cornu1, Olivier Cussenot5, W. Ryan Diver7, Susan M. Gapstur7,
Henrik Grönberg8, Christopher A. Haiman9, Brian Henderson9, Amy Hutchinson2, David J. Hunter10,
Timothy J. Key11, Suzanne Kolb12, Stella Koutros1, Peter Kraft10, Loic Le Marchand13, Sara Lindström10,
Mitchell J. Machiela1, Elaine A. Ostrander14, Elio Riboli15, Fred Schumacher9, Afshan Siddiq16,
Janet L. Stanford12,17, Victoria L. Stevens7, Ruth C. Travis11, Konstantinos K. Tsilidis18, Jarmo Virtamo19,
Stephanie Weinstein1, Fredrik Wilkund8, Jianfeng Xu20, S. Lilly Zheng20, Kai Yu1, William Wheeler21, Han Zhang1,
African Ancestry Prostate Cancer GWAS Consortiumw, Joshua Sampson1, Amanda Black1, Kevin Jacobs1,
Robert N. Hoover1, Margaret Tucker1 & Stephen J. Chanock1
Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of
critical clinical importance for disease prevention and treatment. In a multistage, case-only
genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at
5q14.3 (RASA1, P ¼ 6.49  10  9) and rs78943174 at 3q26.31 (NAALADL2, P ¼ 4.18  10  8).
In a stratiﬁed case–control analysis, the SNP at 5q14.3 appears speciﬁc for aggressive
prostate cancer (P ¼ 8.85  10  5) with no association for nonaggressive prostate cancer
compared with controls (P ¼ 0.57). The proximity of these loci to genes involved in vascular
disease suggests potential biological mechanisms worthy of further investigation.
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P

rostate cancer is the most common cancer diagnosed in
men and second leading cause of cancer death among men
in the United States1; however, little is known about why
the disease progresses in some men but not in others.
Determining which cancers are likely to progress and cause
death is of critical clinical importance. Prostate cancer
aggressiveness is thought to be partially determined by genetic
factors, as studies have shown an increased risk of death from
prostate cancer among offspring with a family history of fatal
disease2,3. The deﬁnitions of aggressive prostate cancer differ
between studies; however, one important and widely used
descriptor is tumour grade at diagnosis, as measured by the
Gleason score, which ranks pathological changes, namely, tumour
differentiation, and has been associated with disease progression
and survival4. Linkage studies using the Gleason score as a
measure of aggressiveness have implicated several chromosomal
regions, including 1p, 5q, 6q, 7q and 19q; however, no speciﬁc
genetic mutations have been conclusively identiﬁed5–8. Although
previous genetic association studies have identiﬁed or suggested
markers for aggressive prostate cancer9–11, these single-nucleotide
polymorphisms (SNPs) have either also been associated with
nonaggressive disease, making them nonspeciﬁc, or have not been
convincingly replicated12.
Genome-wide association studies (GWAS) have successfully
identiﬁed roughly 100 loci associated with prostate cancer
risk11–26; however, most loci have minor allele frequencies
(MAFs) 410% and, so far, none conclusively differentiate
aggressive from nonaggressive disease. To discover additional
loci associated with risk and to identify loci speciﬁc for aggressive
prostate cancer, here we conduct a multistage GWAS for prostate
cancer among men of European ancestry using the Illumina
HumanOmni2.5 Beadchip, which provides greater coverage of
uncommon SNPs for individuals of European ancestry than
microarrays used in previous GWAS of prostate cancer. We
identify two novel loci associated with the Gleason score, a
pathological measure of prostate cancer aggressiveness, that are
located near genes involved in vascular development and
maintenance.
Results
Case–control association results for prostate cancer. A total of
4,600 cases and 2,941 controls of European ancestry from the
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were genotyped using the Illumina HumanOmni2.5
Beadchip and passed rigorous quality-control criteria (see
Methods). Baseline characteristics of the cases and controls are
shown in Supplementary Table 1. On the basis of a linear
regression model, men with higher Gleason scores were more
likely to be diagnosed at an older age (Po0.001). Of the SNPs
genotyped, 1,531,807 passed quality-control ﬁlters with a minimum call rate of 94%. Genotypes were analysed using regression
models, assuming a log-additive genetic model and adjusting for
age and signiﬁcant eigenvectors. A quantile–quantile (Q–Q) plot
of the P values for prostate cancer risk on the basis of logistic
regression models showed enrichment of small P values compared with the null distribution, even after removing SNPs within
500 kb of the previously published loci (Supplementary Fig. 1,
l ¼ 1.007). Fifty-six of the previously published loci were
nominally associated with risk (Po0.05) in stage 1
(Supplementary Table 2), and two previously published loci at
chromosomes 8q24 and 17q12 reached genome-wide signiﬁcance
in stage 1 (Po5  10  8, Supplementary Fig. 2). Rare variant
analysis using SKAT27 for SNPs with MAFo2% revealed ﬁve
gene regions with Po5  10  8; however, all appeared to be
artefacts driven by poorly clustered SNPs.
2

Sixteen promising SNPs with Po2  10  5 on the basis of the
logistic regression models were taken forward for Taqman
replication in 5,139 cases and 5,591 controls from seven studies
(see Methods); however, none replicated for prostate cancer
overall (Supplementary Table 3). A more extensive replication
was undertaken using a custom Illumina iSelect microarray
comprising 51,207 SNPs selected for prostate cancer, 10,458 SNPs
for other phenotypes (for example, obesity) and 1,435 candidate
SNPs (see Methods). In stage 2, a total of 6,575 cases and 6,392
controls from ﬁve studies were genotyped with the custom iSelect
and passed quality-control criteria (Supplementary Table 1). In
silico data were also available for stage 3 for 1,204 nonoverlapping
cases and 1,231 controls from a previous GWAS of advanced
(deﬁned as Gleason score Z8 or stage C/D) prostate cancer12,
giving a total of 12,379 cases and 10,564 controls. As not all SNPs
included on the iSelect were directly genotyped in stage 1 or stage
3, both scans were imputed using the 1000 Genomes Project
release version 3 (ref. 28) and IMPUTE2 (ref. 29).
In a combined meta-analysis of the primary scan together with
the custom SNP microarray replication and in silico look-up in a
previous GWAS, 13 loci reached genome-wide signiﬁcance
(Po5  10  8); however, each of them conﬁrmed a previously
reported locus13–20,23 (Supplementary Table 4). Although not
reaching genome-wide signiﬁcance, two new suggestive loci at
chromosome 16q22.2 (PKD1L3, rs12597458, P ¼ 9.67  10  8)
and 6p22.3 (CDKAL1, rs12198220, P ¼ 2.13  10  7) were also
identiﬁed (Supplementary Table 5, Supplementary Fig. 3).
Further studies are needed to conﬁrm these ﬁndings.
Case-only results of disease aggressiveness. To evaluate disease
aggressiveness, we modelled the Gleason score as a quantitative
trait among the prostate cancer cases (n ¼ 4,545) included in
stage 1 in a case-only analysis using linear regression. We chose to
model the Gleason score as a quantitative trait as opposed to a
dichotomous outcome in order to maximize our statistical power
to detect variants that differentiate aggressive from nonaggressive
disease. In stage 1, the Q–Q plot of the association P values
revealed a small number of SNPs with P values less than expected
under the null distribution (Supplementary Fig. 4, l ¼ 0.998). We
evaluated the SNPs previously reported to be associated with the
risk of aggressive disease; however, none were signiﬁcantly
associated with the Gleason score among cases (Supplementary
Table 6). As part of the custom SNP microarray replication, SNPs
with a P value o0.001 from the linear regression model of the
Gleason score as a quantitative trait, ﬁltered using r240.8, were
taken forward for the custom SNP microarray replication in 5,355
cases with the Gleason score from ﬁve studies (stage 2). One novel
locus at chromosome 5q14.3 (rs35148638) reached genome-wide
signiﬁcance in the meta-analysis of stages 1 and 2. Five SNPs,
including two moderately correlated SNPs at chromosome
5q14.3, with P values o2  10  6, were taken forward for
replication in 2,618 cases from the Cancer of the Prostate in
Sweden study. In the meta-analysis of the Gleason score results
for all three stages including a total of 12,518 cases, three
SNPs reached genome-wide signiﬁcance: rs35148638 at 5q14.3
(P ¼ 6.49  10  9), rs62113212 at 19q13.33 (P ¼ 5.85  10  9)
and rs78943174 at 3q26.31 (P ¼ 4.18  10  8; Table 1). The SNPs
at chromosome 5q14.3 and 3q26.31 represent novel loci (Fig. 1),
whereas the chromosome 19q13.33 locus has been previously
identiﬁed to be associated with prostate cancer risk overall18.
Stratiﬁed case–control association results for novel loci. To
evaluate the extent to which these three loci (identiﬁed from our
case-only study of the Gleason score) could be associated with
aggressive prostate cancer risk, we conducted a case–control
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Table 1 | Loci associated with prostate cancer aggressiveness as measured by the Gleason score among cases only*.
SNP
Novel loci
rs35148638

rs78943174

Nearest
gene(s)

Chr

Position

Risk
allelew

Other
allele

Stage

RAFz

No. of
subjects

Beta

RASA1, CCNH

5q14.3

86610989

C

A

0.25
0.255
0.262

NAALADL2

3q26.31

175252736

C

T

Stage 1
Stage 2
Stage 3
Combined
Stage 1
Stage 2
Stage 3
Combined

4,545
5,353
2,618
12,516
4,545
5,336
2,604
12,485

0.085
0.125
 0.025
0.088
0.361
0.217
0.293
0.289

0.024 3.09  10  4
0.022 1.86  10  6
0.040
0.50
0.015 6.49  10  9
0.085 2.44  10  5
0.085
0.03
0.110
0.008
0.053 4.18  10  8

19q13.33

51360840

T

C

4.544
5,348
2,616
12,508

0.177
0.124
0.119
0.138

0.043 4.00  10  5
0.041
0.009
0.040
0.004
0.024 5.85  10  9

Previously reported loci
rs62113212
KLK3

0.985
0.987
0.979

Stage 1
0.063
Stage 2 0.061
Stage 3 0.107
Combined

SE

P-value

*Results from case-only analysis of the Gleason score as a quantitative trait using linear regression.
wRisk allele is the allele associated with an increased risk of aggressive disease (that is, higher Gleason score).
zFrequency of the risk allele.

analysis stratiﬁed by the overall Gleason score (that is, scores of
2–10), recognizing that our power to detect an association at
genome-wide signiﬁcance would be reduced. We did not have
data on the individual components of Gleason 7 from most
studies in order to subclassify them as 3 þ 4 or 4 þ 3, and so in
order to clearly differentiate between aggressive and nonaggressive disease, we stratiﬁed our cases by those with Gleason
scores r6 (nonaggressive) and those with Gleason Z8 (aggressive). Although it did not reach genome-wide signiﬁcance,
rs35148638 at 5q14.3 showed an increased risk with aggressive
prostate cancer (P ¼ 8.85  10  5; Supplementary Table 7). There
was no association for nonaggressive disease (P ¼ 0.57) and the P
value for heterogeneity between the two outcomes was modestly
signiﬁcant (P ¼ 2.89  10  4). As rs78943174 at 3q26.31 was not
common among controls with a MAF of 1–2%, we had limited
power to detect an association with aggressive disease; however,
we did observe a marginal positive association between
rs78943174 and aggressive prostate cancer risk (P ¼ 0.07) and the
P value for heterogeneity between aggressive and nonaggressive
prostate cancer risk was nominally signiﬁcant (P ¼ 0.006). Consistent with previous studies30, the SNP at 19q13.33 was strongly
associated with nonaggressive prostate cancer (P ¼ 3.51  10  13)
with a weak association in the opposite direction for aggressive
prostate cancer (P ¼ 0.01) and highly signiﬁcant P value for
heterogeneity (P ¼ 1.44  10  10).
As African Americans have an elevated risk of prostate cancer,
we evaluated the extent to which these three SNPs were associated
with aggressive prostate cancer risk in African Americans using
data from the African American Prostate Cancer GWAS
Consortium (see Methods). In this smaller study, none of the
SNPs were signiﬁcantly associated with the risk of aggressive
disease (Supplementary Table 8), and only rs62113212 at
chromosome 19q13.33 was nominally associated with nonaggressive disease (P ¼ 0.04). However, the direction of the effects
for African Americans for the SNPs at 3q26.31 and 19q13.33 were
consistent with what we observed among Europeans.
Further examination of novel loci. Examination of the three
identiﬁed loci for the Gleason score using data from ENCODE
revealed signiﬁcant DNase enrichment in lymphoblastoid and
embryonic myoblast cells and evidence for altered motifs
(Supplementary Table 9). Rs62113212 at 19q13.33 is in strong
linkage disequilibrium with a missense SNP (rs17632542, r2 ¼ 1).

No signiﬁcant expression quantitative trait locus (eQTL) associations were observed using data from the Genotype-Tissue
Expression (GTEx) Project31; however, for a proxy of rs35148638
at 5q14.3 (rs4421140, r2 ¼ 0.82), we did ﬁnd nominally signiﬁcant
eqtl associations with RASA1 and CCNH expression and meqtl
associations with CpG sites in RASA1 and CCNH in adipose
tissue32,33.
Discussion
Linkage studies of prostate cancer aggressiveness have reported
suggestive evidence of linkage to chromosome 5q (refs 5–8) and
speciﬁcally 5q14 in TMPRSS2-ERG fusion-positive families34.
The 5q14.3 SNP identiﬁed in this study (rs35148638), associated
with disease aggressiveness, is intronic to the RAS p21 protein
activator 1 (RASA1) gene, which suppresses RAS function, helps
regulate cellular proliferation and differentiation35, and controls
blood vessel growth36. Rare mutations in RASA1 lead to capillary
malformation-arteriovenous malformation and Parkes–Weber
syndrome37 as well as lymphatic abnormalities38, providing an
intriguing plausibility for the gene in aggressive prostate
cancer. The SNP is also B79 kb downstream of the cyclin H
(CCNH) gene, which encodes a regulatory component of a
cyclin-dependent (CDK)-activating kinase necessary for RNA
polymerase II transcription, nucleotide excision repair and p53
phosphorylation39. CCNH has been shown to be differentially
expressed between androgen-sensitive and androgen-resistant
prostate cancer cell lines40,41, suggesting a role in prostate cancer
progression.
The 3q26.31 SNP (rs78943174) is intronic to the N-acetylated
alpha-linked acidic dipeptidase-like2 (NAALADL2) gene, which is
part of the glutamate carboxypeptidase II family. This gene is
also related to prostate-speciﬁc membrane antigen, a wellcharacterized diagnostic indicator and potential drug target of
prostate cancer42. NAALADL2 has been shown to promote a
pro-migratory and pro-metastatic microenvironment, and
higher tumour expression of NAALAD2 is associated with
higher Gleason score and poor survival following radical
prostatectomy43. Variants in NAALADL2 have also been
identiﬁed to be associated with Kawasaki disease44, a paediatric,
autoimmune vascular disease. The SNP is also B117 kb telomeric
of the microRNA, MIR4789, which is predicted to target several
genes involved in the insulin resistance (for example, IRS1,
PIK3R1) among others45,46. A previous GWAS of prostate cancer
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Figure 1 | Regional association plots of the two novel loci associated with the Gleason score as a quantitative trait among cases. (a) Chromosome
5q14.3 (rs35148638) and (b) chromosome 3q26.31 (rs78943174). Shown are the –log10 association P values from the linear regression model for the 4,545
cases in stage 1 (dots and lower purple diamond) and –log10 P values from the linear regression model for the 12,518 cases in the combined stage 1–3
analysis (upper diamond).

reported a suggestive association with a SNP at 3q26.31 (ref. 47);
however, this SNP is not in linkage disequilibrium with the SNP
identiﬁed in our study (r2 ¼ 0.003).
The chromosome 19q13.33 (KLK3) locus has been previously
associated with prostate cancer risk overall18. Although several
studies have suggested that the risk may differ by disease
aggressiveness30,48–50, this study shows for the ﬁrst time a
genome-wide signiﬁcant difference between aggressive and
nonaggressive disease as measured by the Gleason score. KLK3
encodes the prostate-speciﬁc antigen (PSA) protein. The C allele
of rs62113212 has been shown to be associated with higher PSA
levels48, suggesting that the association observed with the SNP is
related to early prostate cancer detection.
Although one of our goals was to identify uncommon variants
for prostate cancer, we did not identify any new independent
SNPs with a MAF o10%. We did, however, identify a suggestive
4

locus at chromosome 6p22.3 (rs12198220), which is 98 kb
downstream of CDKAL1. A pooled linkage study of prostate
cancer previously reported suggestive evidence of linkage to this
region51. Interestingly, SNPs at this locus have been associated
with the risk of type 2 diabetes, adding to the list of susceptibility
regions shared between prostate cancer and type 2 diabetes52. We
also discovered a new suggestive locus at 16q22.2, which is in
strong linkage disequilibrium with a missense variant (rs3213422,
r2 ¼ 0.74) in dihydro-orotate dehydrogenase (quinone) gene
(DHODH), which encodes an enzyme necessary for the
biosynthesis of pyrimidines and cell proliferation. Further
studies are needed to conﬁrm these suggestive loci.
In this study, we used the Gleason score to differentiate
between nonaggressive and aggressive prostate cancer. Gleason
score is a powerful prognostic factor and predictor of disease
behaviour; however, substantial changes in Gleason scoring have
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changed since it was ﬁrst proposed over 40 years ago, resulting in
shifts towards higher scores53. In addition, differences in scoring
between pathologists remain54. Whether these changes in
Gleason scoring ultimately result in better outcome prediction
and classiﬁcation of disease from an aetiologic standpoint
remains to be seen. Unlike for breast cancer where classiﬁcation
by receptor status has resulted in signiﬁcant advances in the
aetiologic understanding of the disease, clearly deﬁning aggressive
prostate cancer remains difﬁcult. Regardless, the Gleason score is
an important component of prostate cancer risk assessment and
is the most commonly used tool for assessing prostate cancer
aggressiveness.
In conclusion, we identiﬁed two new loci associated with
prostate cancer aggressiveness as measured by the Gleason score
in a case-only study of prostate cancer. Although additional
studies are needed to conﬁrm these ﬁndings and reveal the
underlying biological mechanism, the proximity of these SNPs to
genes involved in vascular disease, cell migration and metastasis
makes them intriguing loci for further study.
Methods
Stage 1: discovery population and genotyping. A new GWAS was conducted in
prostate cancer cases and controls of European ancestry from the PLCO Cancer
Screening Trial. PLCO is a randomized trial for the early detection of prostate,
lung, colorectal and ovarian cancers55. In brief, 76,693 men were enrolled in the
trial from 10 centres in the United States from 1993 to 2001 and randomized to
receive annual screening with PSA for 6 years and digital rectal examination for 4
years or referred to their physician for routine care. Men with positive screening
results were referred to their primary physician for further evaluation. All prostate
cancer cases detected during screening or reported during the trial were
pathologically conﬁrmed, and information on stage and grade was abstracted from
medical records. Blood or buccal cells were collected from participants in the
trial56. The study was approved by the institutional review board at each centre and
National Cancer Institute (NCI); all study participants provided informed written
consent.
A total of 4,838 prostate cancer cases and 3,053 controls of European ancestry,
matched on age and year of randomization, were selected for stage 1. The sample
size was chosen on the basis of statistical power estimates for detecting a modest
association in a multistage GWAS. Including quality-control duplicates, 8,222
samples were genotyped on the Illumina HumanOmni2.5 Beadchip. Extensive
quality-control metrics were employed to ensure that only high-quality genotype
data were analysed using the GLU software package. Samples with a missing rate
46% (n ¼ 323) or heterozygosity o16% or 421% (n ¼ 7) were excluded, and 221
samples were removed because of technical issues. Gender discordance on the basis
of chromosome X heterozygosity was evaluated; however, no subjects were
removed. One unexpected duplicate (499.9% concordance) and 28 full sibling
pairs on the basis of an identity-by-descent threshold of 0.70 were detected and one
subject from each pair was removed (n ¼ 29). Ancestry was estimated using a set of
population informative markers57 and the GLU struct.admix module, which is
similar to the method proposed in (ref. 58). Five subjects (three cases and two
controls) were determined to have o80% European ancestry and were removed
from analysis (Supplementary Fig. 5). Principal components analysis was
performed to evaluate population substructure in greater detail (Supplementary
Fig. 6), and two signiﬁcant eigenvectors (Po0.05) were included in the analytic
model. Expected duplicates yielded 99.9% concordance. SNPs without genotype
calls, a completion rate o94%, Hardy–Weinberg proportion test P value
o1  10  8 or MAFo1% were excluded, leaving 1,531,807 SNPs for analysis.
After quality-control exclusions, 4,600 cases and 2,840 controls remained. An
additional 101 male controls from PLCO Cancer Screening Trial, genotyped
previously on the HumanOmni2.5 (ref. 59) were also included, resulting in 4,600
cases and 2,941 controls for the primary prostate cancer analysis (Supplementary
Table 1 and Supplementary Fig. 7). Of those cases, 4,545 men had information on
the Gleason score available. Regression models were ﬁt adjusting for signiﬁcant
principal components and age. Sixteen different models were ﬁtted for prostate
cancer-related outcomes, including overall prostate cancer risk and Gleason score.
Stage 2: follow-up studies and genotyping. Replication was conducted using a
set of independent prostate cancer cases and controls from ﬁve studies: AlphaTocopherol, Beta-Carotene Cancer Prevention Study60 (ATBC, n ¼ 1,092 cases/
1,099 controls), Cancer Prevention Study II (ref. 61; CPSII, n ¼ 2,770 cases/2,669
controls), Health Professional Follow-up Study62 (n ¼ 963 cases/1,047 controls),
French Prostate Cancer Case–Control Study (n ¼ 1,494 cases/1,546 controls) and
PLCO55 (n ¼ 990 cases/922 controls). Including quality-control duplicates, 14,592
samples were genotyped using a custom Illumina iSelect microarray comprising
51,207 SNPs selected for prostate cancer, 10,458 SNPs for other phenotypes (for

example, smoking and obesity) and 1,435 candidate SNPs. The SNPs for prostate
cancer were ﬁltered using r2o0.7 and selected on the basis of the most signiﬁcant
results from 16 prostate cancer models, with the primary models being an overall
prostate cancer risk model assuming a log-additive effect for each SNP and caseonly Gleason score model, where Gleason was modelled as a quantitative linear
trait among cases and each SNP was assumed to have an additive effect. SNPs with
P values o0.05 and o0.001 from each model, respectively, were advanced for
possible replication.
Similar to stage 1, samples genotyped in stage 2 underwent rigorous qualitycontrol procedures. Samples with missing rate 410% (n ¼ 1,158) or mean
heterozygosity o20% or 426% (n ¼ 4) were excluded. In addition, 21 subjects
without phenotype information were removed. Fifteen unexpected duplicates with
concordance rates 499.9% were observed, and 25 ﬁrst-degree relative pairs were
detected assuming an identity-by-descent threshold of 0.7. For each unexpected
duplicate and relative pair, one subject was removed. Using the GLU struct.admix
module, ancestry was estimated on the basis of genotyped SNPs with a MAF410%
and HapMap data as the ﬁxed reference population. Sixty-six subjects with o80%
European ancestry were removed from the analysis. Principal components analysis
was conducted using a set of SNPs selected for traits unrelated to prostate cancer
(for example, smoking and alcohol intake). After quality-control exclusions,
a total of 6,575 cases and 6,392 controls remained for the primary analysis
(Supplementary Table 1), including 5,355 cases with the Gleason score. SNPs with
a MAFo1% or completion rate o90% were excluded from the analysis, leaving
55,497 SNPs for analysis (Supplementary Fig. 7). Regression models were ﬁt
adjusting for age, signiﬁcant principal components and study.
In addition to the custom SNP microarray replication, 16 promising SNPs
(Po2  10  5) were taken forward for fast-track replication in the ﬁve studies
listed above (n ¼ 2,495 cases/2,532 controls) as well as three additional studies:
Agricultural Health Study63 (n ¼ 579 cases/1,172 controls), Fred Hutchinson
Cancer Research Center (n ¼ 1,315 cases/1,152 controls) and the Multiethnic
Cohort64 (n ¼ 750 cases/735 controls). In total, 5,139 cases and 5,591 controls, all
of European ancestry, were genotyped (Supplementary Fig. 7). The SNPs were
genotyped using individual TaqMan assays (Applied Biosystems Inc) and
quality-control duplicates yielded 499.9% concordance.

Stage 3a: in silico replication of prostate cancer ﬁndings. For replication of the
overall prostate cancer results, nonoverlapping in silico GWAS data were available
from 1,204 cases and 1,231 controls of European ancestry from four studies from a
previous GWAS of advanced prostate cancer12: European Prospective Investigation
into Cancer and Nutrition (EPIC; 431 cases/426 controls)65, Multiethnic Cohort
(244 cases/259 controls)64, Physicians Health Study (PHS; 298 cases/255 controls)
and American Cancer Society Cancer Prevention Study II (CPSII; 231 cases/291
controls not included in stage 2)61 (Supplementary Fig. 7). Subjects were genotyped
using the Illumina HumanHap610K and extensive quality-control ﬁlters applied as
described previously. All data were imputed using IMPUTE2 (ref. 29) and 1000
Genomes Project release version 3 (ref. 28) as the reference panel, and data
analysed using SNPTEST assuming a log-additive genetic model and adjusting for
age, study and signiﬁcant principal components. Only SNPs with an information
score 40.3 were included in the meta-analysis.

Stage 3b: additional replication for Gleason score ﬁndings. For further
replication of the results for the Gleason score, we genotyped ﬁve of the most
signiﬁcant SNPs (Po2  10  6) in the Cancer of the Prostate in Sweden, a
population-based case–control study of 2,618 cases and 1,728 controls using
Sequenom (Supplementary Fig. 7). Regression models were ﬁt adjusting for age.

Meta-analysis. Data from all three stages were meta-analysed using the ﬁxed
effects inverse variance method based on the beta estimates and s.e.’s from each
stage.

Further follow-up analyses. To evaluate the associations observed in our study of
men of European ancestry with those observed in African Americans, we obtained
association results for three genome-wide signiﬁcant hits from the African
American Prostate Cancer GWAS Consortium22. Although it was not possible to
evaluate the Gleason score as a quantitative trait among cases in this consortium,
we were able to obtain stratiﬁed association results for cases with Gleason r6
versus controls and cases with Gleason Z8 versus controls.
Using 1000 Genomes Project data, we identiﬁed SNPs with r240.8 with the
lead SNPs identiﬁed to be associated with Gleason score and evaluated whether
they were nonsynonymous coding variants. We utilized HaploReg66 to assess
noncoding functional markers in the regions containing our lead SNPs and related
proxy SNPs (r240.8; Supplementary Table 9). We explored possible cis eQTL
associations with our lead SNPs and related proxy SNPs (r240.8) in adipose tissue,
lymphoblastoid cell lines and skin using data from the MuTHER resource32 and all
available tissues, including whole blood, in the GTEx31. We also examined possible
methylation eQTL associations in adipose tissue using the MuTHER resource33.
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